Uterine Fibroid Treatment Market Report

The growing demand of patients for minimally and non-invasive fibroids surgeries is projected to drive market expansion. Minimal incisions reduce post-operative pain and faster recovery, leading to greater use of these treatments. Numerous prominent firms are investing in R&D to bring innovative minimally and non-invasive surgical devices to market. As per Frontiers in Medicine, between 40 to 60% of women under the age of 35 are expected to have UFs. For example, one of the incisionless techniques frequently suggested by physicians is MR-guided Focused Ultrasound (MRgFUS) for the treatment of uterine fibroids. The device emits ultrasonic beams during this surgery, heating and removing specific tissue from the uterine cavity. As a result of the reduced pain, effectiveness, lower risk of infection and faster recovery time compared to open surgeries, the market for uterine fibroids treatment devices is expected to rise.

However, breakthroughs such as hysteroscopic myomectomy and laparoscopic myomectomy are changing the way uterine fibroids are treated, providing less invasive options compared to conventional surgery. Hysteroscopic myomectomy is the process of extracting fibroids by inserting a slender, illuminated tube known as a hysteroscope through the vaginal canal, which helps to reduce recovery time and eliminate the need for abdominal incisions. In contrast, laparoscopic myomectomy uses small incisions and a camera to direct the surgical tools, leading to less postoperative pain and scarring than open surgery. These methods improve patient access by increasing the availability of treatment options for those looking for faster recovery and less invasive procedures. As these techniques become more popular, they are expanding the range of successful fibroid treatment options and enhancing patient results and contentment.

Complications caused by using morcellators might provide a major barrier in the uterine fibroids treatment industry. Although laparoscopic power morcellators are commonly used during myomectomy and hysterectomy procedures, they can cause issues such as metastatic leiomyosarcoma cancer. These possible restrictions hamper the global uterine fibroids treatment market's overall expansion. Nevertheless, continuous advancements in medical sciences and technology, as well as untapped potential in developing markets, offer promising growth opportunities.

Furthermore, the high cost of treatment such as MRI-guided focused ultrasound (MRgFUS) and laparoscopic myomectomy, makes it difficult for a lot of patients to access them. For instance, MRgFUS may have the treatment cost over US$10,000 per session, a significant cost that insurance may not always cover. In the same way, laparoscopic myomectomy, although less invasive, frequently involves significant costs associated with hospital charges and skilled surgical teams. In 2023, data indicated that numerous patients in rural or disadvantaged areas face challenges in paying for such advanced choices, restricting their treatment options and affecting the overall availability of care.

Recent breakthroughs underscore the pressing necessity for enhanced solutions. Innovative drug formulations like SPRMs and targeted therapies provide promise for better symptom control with reduced side effects. Furthermore, advanced techniques such as MRI-guided focused ultrasound (MRgFUS) and laparoscopic myomectomy indicate a move towards less invasive therapies, offering patients options that lower both recovery periods and surgical dangers. For instance in  January 2024, ynesonics, Inc. a privately-held women’s healthcare medical device company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that with the support of the American College of Obstetrics and Gynaecology (ACOG), the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code, 58580, for transcervical uterine fibroid ablation with ultrasound guidance using radiofrequency. In addition, In January 2024, In partnership with Sumitomo Pharma Canada, Inc., Pfizer Canada ULC is proud to announce that supply of MYFEMBREE (relugolix 40 mg, estradiol 1 mg and norethindrone acetate tablets 0.5 mg tablets) is now available in Canada by prescription for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, as well as for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

The existence of well-established healthcare facilities in the region, increased government efforts and an increase in hysterectomy-related surgical procedures/hospital visits are all fueling the market in North America. Additionally, the existence of major firms like as Medtronic, Stryker and CooperSurgical, Inc., as well as the availability of technologically advanced items, all contribute to the region's market growth. Furthermore, the region's ease access to healthcare technologies and strong distribution channels help to uterine fibroids treatment device adoption. In recent years, countries such as the United States and Canada have seen an increase in the number of uterine fibroids cases and treatments. According to The Johns Hopkins University, around half a million hysterectomies are conducted in the United States each year. Furthermore, according to the Journal of Obstetrics and Gynecology Canada (JOGC), over 41, 000 hysterectomies are performed in Canada each year. Since uterine fibroids treatment devices are required to execute such treatments, the market is expected to rise throughout the forecast period.